某三甲医院住院消化道肿瘤患者抗凝预防现状调查与分析

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (520 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To retrospectively investigate and analyze the current status of anticoagulant prevention in hospitalized patients with gastrointestinal tumors, and to explore the role that clinical pharmacists played in the prevention of venous thromboembolism (VTE) in hospitalized patients with gastrointestinal tumors. Methods A random number table was used to select 120 patients with gastrointestinal tumors hospitalized in a tertiary hospital in Shanghai from July to December 2019, the risk of venous thrombosis was evaluated, and the use of anticoagulant drugs in the patients were retrospectively investigated and analyzed. Results The Caprini score scale was used in 46 cases for surgical patients; the Khorana score scale was used for cancer chemotherapy patients, a total of 41 cases; and the Padua score scale was used for medical inpatients, a total of 33 cases. Among 120 patients, Nadroparin or Rivaroxaban for preventive anticoagulation was chosen by 19 cases. According to the Caprini score, 45 patients with high-risk tumors ≥3 points were obtained, of which 17 were given preventive anticoagulation; 41 patients with Khorana score ≥1 point were medium-high-risk patients, and there were no patients with preventive anticoagulation; there were 13 high-risk patients with Padua score ≥4 points, and 1 case of preventive anticoagulation. Conclusion The overall rate of anticoagulation prevention for patients with gastrointestinal tumors in the hospital is relatively low. Clinical pharmacists should strengthen the education of tumor-related VTE in clinical departments, improve clinicians’ awareness of preventing anticoagulation, reduce the incidence of VTE in patients with malignant gastrointestinal tumors and improve their survival rate.

Key words： Gastrointestinal cancer Venous thromboembolism Anticoagulation Prevention Clinical pharmacists

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TAO Jieyu CHENG Xuefang LI Qin ZHOU Yan

Cite this article:

TAO Jieyu CHENG Xuefang LI Qin ZHOU Yan. Investigation and analysis of the current status of anticoagulation prevention for inpatients with gastrointestinal tumors in a tertiary hospital#br#[J]. 中国医药导报, 2021, 18(35): 63-67.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I35/63

[1] Haley MP. Overview of venous thromboembolism [J]. Am J Manag Care，2017，23（20 Suppl）：S376-S382.
[2] Mahajan A，Brunson A，White R，et al. The Epidemiology of Cancer-Associated Venous Thromboembolism：An Update [J]. Semin Thromb Hemost，2019，45（4）：321-325.
[3] Walker AJ，Card TR，West J，et al. Incidence of venous thromboembolism in patients with cancer -a cohort study using linked United Kingdom databases [J]. Eur J Cancer，2013，49（6）：1404-1413.
[4] Zayed MA，De Silva GS，Ramaswamy RS，et al. Management of cavoatrial deep venous thrombosis：incorporating new strategies [J]. Semin Intervent Radiol，2017，34（1）：25-34.
[5] 马军，吴一龙，秦叔逵，等.中国肿瘤相关静脉血栓栓塞症预防与治疗专家指南（2015版）[J].中国实用内科杂志，2015，35（11）：907-920.
[6] Khorana AA，Francis CW，Culakova E，et al. Frequency，risk factors，and trends for venous thromboembolism among hospitalized cancer patients [J]. Cancer，2007，110（10）：2339-2346.
[7] Chew HK，Wun T，Harvey D，et al. Incidence of venous thrombo- embolism and its effect on survival among patients with common cancers [J]. Arch Intern Med，2006， 166（4）：458-464.
[8] 白阳，陈虹.恶性肿瘤相关静脉血栓栓塞症的预防和治疗[J].国际呼吸杂志，2020（1）：5-10.
[9] Hisada Y，Mackman N. Cancer-associated pathways，and biomarkers of venous thrombosis [J]. Blood，2017，130（13）：1499-1506.
[10] 李致玲，李桂香.消化道肿瘤与凝血功能的研究进展[J].中国卫生产业，2014，11（22）：197-198.
[11] 马军，秦叔逵，吴一龙，等.肿瘤相关静脉血栓栓塞症预防与治疗指南（2019版）[J].中国肿瘤临床，2019，46（13）：653-660.
[12] Kearon C，Akl EA，Ornelas J，et al. Antithrombotic therapy for vte disease：Chest guideline and expert panel report [J]. Chest，2016，149（2）：315-352.
[13] 滕晓菊，徐姝娟，杨雨薇，等.Caprini风险评估量表对外科VTE患者的流行病学调查[J].人人健康，2020（11）：73-74.
[14] Donnellan E，Khorana AA. Cancer and Venous Thromboembolic Disease：A Review [J]. Oncologist，2017，22（2）：199-207.
[15] Gerotziafas GT，Papageorgiou L，Salta S，et al. Updated clinical models for VTE prediction in hospitalized medical patients [J]. Thromb Res，2018，164（Suppl 1）：S62-S69.
[16] NCCN. Cancer-Associated Venous Thromboembolic Disease（Version 1. 2019）[J]. J Natl lempt Canc Netw，2019.
[17] Langer F，Bokemeyer C. Crosstalk between cancer and haemostasis：Implications for cancer biology and cancer-associated thrombosis withfocus on tissue factor [J]. Hamostaseol，2012，32（2）：95-104.
[18] Geerts WH，Pineo GF，Heit JA，et al. Prevention of venous thromboembolism：the seventh ACCP conference on antithrombotic and thrombolytic therapy [J]. Chest，2004， 126（3 Suppl）：338s-400s.
[19] Khorana AA. Venous thromboembolism prevention in cancer outpatients [J]. J NCCN，2013，11（11）：1431-1438.
[20] Stuck AK，Spirk D，Schaudt J，et al. Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review [J]. Thromb Haemost，2017， 117（4）：801-808.
[21] Nigel SK，Alok AK，Kuderer NM，et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer：ASCO Clinical Practice Guideline Update [J]. J Clin Oncol，2020，38（5）：496-520.
[22] 魏晓霞，阳丽梅，蔡加琴，等.某院住院肿瘤患者静脉血栓栓塞症预防现状的调查分析[J]中国医院药学杂志，2017，37（12）：1185-1188.
[23] 刘峰，袁波，苏巧俐，等.成人消化道出血合并恶性肿瘤患者出血病因分析[J].浙江医学，2016，38（12）：994-996.
[24] 中国抗癌协会临床肿瘤学协作专业委员会.肿瘤化疗所致血小板减少症诊疗中国专家共识（2014版）[J].中华肿瘤杂志，2014，36（11）：876-879.
[25] 严婧文，袁媛，陈倩，等.直接口服抗凝药在静脉血栓栓塞症防治中的临床应用[J].中华结核和呼吸杂志，2020， 43（2）：140-145.
[26] Yee J，Kaide CG. Emergency Reversal of Anticoagulation [J]. West J Emerg Med，2019，20（5）：770-783.